Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis

NCT ID: NCT04535427

Last Updated: 2020-09-02

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 144 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-01-01
• Study Completion Date: 2023-12-31

Brief Summary

To investigate the role of L-arginine supplementation in the treatment of DMARDs-refractory moderate to severe rheumatoid arthritis

Conditions

Rheumatoid Arthritis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Control

Participants in this arm will receive placebo per day.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Low dose L-arginine

Participants in this arm will receive 9g (3g tid) L-arginine per day.

Group Type: EXPERIMENTAL

L-arginine

Intervention Type: DRUG

Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

High dose L-arginine

Participants in this arm will receive 15g (5g tid) L-arginine per day.

Group Type: EXPERIMENTAL

L-arginine

Intervention Type: DRUG

Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Interventions

L-arginine

Low (3g every time, 3 times a day)or high dose (5g every time, 3 times a day) of L-arginine will be administered to the experimental groups for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Intervention Type: DRUG

Placebo

Placebo will be administered to the control group for at least 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

In order to be eligible for inclusion in this study, subjects must meet all of the following criteria:

• Chinese RA patients who are between 18 and 45 years old (inclusive) when signing the consent form, with a body mass index between 19 and 29 kg/m2 (inclusive), and weigh between 60 and 90 kg.
• The subject must be diagnosed with RA, and the judgment standard meets the 2010 American College of Rheumatology (ACR)/European Alliance Against Rheumatism (EULAR) RA classification standard;
• Active RA is defined as having ≥ 6 swollen joints and ≥ 6 tender joints at screening and baseline (based on 66/68 joints, excluding distal interphalangeal joints), and at least one of the following conditions occurs during screening: ESR ≥ 28 mm/hr, or serum CRP> 10 mg/L;
• Positive rheumatoid factor or anti-cyclic citrulline peptide (CCP) during screening;
• Before using the study drug, the subject must have used MTX continuously for ≥ 12 weeks and have been stable for at least 8 weeks.
• 10-15mg/week dose and willing to use a stable dose throughout the study;
• Patients with moderate to severe disease activity after the current treatment of DMARDs, DAS28-ESR/CRP>3.2;
• Subjects taking oral corticosteroids (≤ 10 mg of prednisone or equivalent) should use a stable dose for ≥ 4 weeks before screening;
• If subjects are taking non-steroidal anti-inflammatory drugs (NSAIDs) or low-efficiency analgesics, such as tramadol, neuronal cell compounds, they must use a stable dose for ≥ 2 weeks before screening.
• Considered as eligible subjects based on the following tuberculosis screening criteria:

1. The subject has no history of latent or active tuberculosis before screening,

2. No signs or symptoms of active tuberculosis in the history and/or physical examination,

3. Have not had close contact with patients with active tuberculosis recently,

4. One chest radiograph (including anteroposterior and lateral views) taken within three months before the administration of the study drug, and qualified radiologists have confirmed that there are no active tuberculosis foci or old inactivated tuberculosis foci.

• Non-smokers, or agree to smoke no more than 10 cigarettes or no more than 2 cigars per day during the entire study period. Note: According to the rules and regulations of the research center, smoking may be prohibited during hospitalization;
• Agree to abstain from alcohol within 48 hours before the administration of the study drug and during the study hospitalization, and agree to drink no more than 10g of alcohol per day during the rest of the study;
• Agree to limit caffeine intake, with a daily limit of five cups of tea, or three cups of coffee or six cans of cola. Do not take caffeine within 4 hours before receiving the electrocardiogram;
• Agree to fully use birth control measures to prevent pregnancy (such as birth control pills, uterine contraceptive devices, or protective measures using spermicides) for at least six months after receiving study drug treatment;
• Except for taking acetaminophen and previously taken multivitamins at the recommended dose, as well as the drugs approved by the investigator and medical monitor, the subject agreed to not use prescription drugs for 14 days before receiving the study drug treatment until the end of the study , Over-the-counter medicines, herbal medicines, proprietary Chinese medicines or "natural" medicines;
• Demonstrate a clear understanding of the research and sign an informed consent (ICF);
• Personal willingness and ability to comply with the study follow-up schedule and other requirements of the study protocol.

Exclusion Criteria

Subjects who meet any of the following criteria should not be selected for this study:

• RA patients combined with hypotension.
• RA patients combined with renal tubular acidosis and electrolyte imbalance.
• RA patients with significant gastrointestinal symptoms.
• According to the judgment of the main investigator, the subject is in a latent physical or psycho-medical state and will not be able to complete the study.
• Have had major surgery or traumatic surgery within 12 weeks before screening.
• Have received an organ transplant (except for corneal transplantation for more than three months before administration).
• Donated blood within 56 days before screening (the blood donation volume is not less than 500 mL).
• Currently suffering from malignant tumors or a history of malignant tumors.
• A history of known lymphoproliferative diseases, including lymphoma or possible signs and symptoms of lymphoproliferative diseases, such as lymphadenopathy and/or splenomegaly.
• Have a recent history of alcohol or drug abuse (within the previous 6 months).
• Positive urine toxicology screening for drugs of abuse include: cocaine, cannabidiol, phencyclidine, amphetamine, methamphetamine, benzodiazepines, barbiturates, opioids, and C Oxyphene, methaqualone, methadone and tricyclic antidepressants.
• When admitted to the research center before the study drug was administered, the urine alcohol screening or breath alcohol test results were positive.
• Have a history of latent or active granulomatous infection before screening, including histoplasmosis or coccidioidomycosis.
• Have a history of known or suspected intolerance or hypersensitivity to any biological drug treatment.
• Chest x-ray pictures taken within 3 months before the first administration of the study drug showed abnormalities suggesting malignant tumors or current active infections (including TB).
• Have nontuberculous mycobacteria or opportunistic infections (such as cytomegalovirus, pneumocystis disease, aspergillosis) within 6 months before screening.
• Have or have had a serious infection (such as sepsis, pneumonia, or pyelonephritis) or were hospitalized for infection or received fourth-generation antibiotic treatment within 2 months before screening.
• A history of chronic or recurrent infectious diseases, including but not limited to the following diseases: chronic kidney infection, chronic chest infection (for example, bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic non-dilated bladder) Inflammation), or open, draining or infectious skin wounds or ulcers.
• Serum was positive for HIV-1 or HIV-2, hepatitis B virus (HBV) or hepatitis C virus (HCV) during screening.
• Syphilis (Treponema pallidum) test (qualitative test) was positive at screening.
• The staff of the main researcher or research center and directly participate in the research or other research of the main researcher or research center, including the staff or the family members of the main researcher.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

RenJi Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Xiaoxiang Chen, PhD

Role: PRINCIPAL_INVESTIGATOR

Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Locations

Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, , China

Countries

China

Central Contacts

Xiaoxiang Chen, PhD

Role: CONTACT

xiaoxiang0721@126.com

0086 13801974325

Facility Contacts

Xiaoxiang Chen, Doctor

Role: primary

xiaoxiang0721@126.com

0086 13801974325

References

Hannemann N, Cao S, Eriksson D, Schnelzer A, Jordan J, Eberhardt M, Schleicher U, Rech J, Ramming A, Uebe S, Ekici A, Canete JD, Chen X, Bauerle T, Vera J, Bogdan C, Schett G, Bozec A. Transcription factor Fra-1 targets arginase-1 to enhance macrophage-mediated inflammation in arthritis. J Clin Invest. 2019 Apr 16;129(7):2669-2684. doi: 10.1172/JCI96832.

Reference Type: BACKGROUND

PMID: 30990796 (View on PubMed)

Other Identifiers

L-ARG-RA

Identifier Type: -

Identifier Source: org_study_id